{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:14:21Z","timestamp":1792026861030,"version":"4.4.0"},"reference-count":23,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4094,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2000,11]]},"abstract":"<jats:p>Despite national guidelines for treatment of hyperlipidemia, significant numbers of individuals with coronary artery disease are not treated to their National Cholesterol Education Program (NCEP) low\u2010density lipoprotein (LDL) goals. The potential benefits of a clinical pharmacist\u2010managed lipid clinic would be to improve rates of success in achieving these goals, improve drug adherence and compliance with therapy, and reduce cardiovascular events. All patients who had a documented history of coronary artery disease and were under the care of one cardiologist were treated in the pharmacist\u2010managed lipid clinic. A second cardiologist provided usual care to a group of patients with coronary artery disease who served as controls. Patients in each arm were followed for a minimum of 6 months. A protocol for therapy changes in clinic patients was developed by the clinical pharmacist and approved by the cardiologist. At the end of 6 months, 69% of patients in the pharmacist\u2010managed clinic achieved their LDL goal, compared with 50% of controls. Compliance with laboratory tests and drug regimens also improved in clinic patients. Compliance with lipid panels went from 8% 2 months before to 89% 2 months after the start of the study. At the end of 6 months compliance with laboratory work and refills was 80%. Thus the clinical pharmacist\u2010managed clinic was highly successful in achieving NCEP goals for secondary prevention.<\/jats:p>","DOI":"10.1592\/phco.20.17.1375.34895","type":"journal-article","created":{"date-parts":[[2004,6,15]],"date-time":"2004-06-15T15:27:47Z","timestamp":1087313267000},"page":"1375-1383","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Effect of a Clinical Pharmacist\u2010Managed Lipid Clinic on Achieving National Cholesterol Education Program Low\u2010Density Lipoprotein Goals"],"prefix":"10.1002","volume":"20","author":[{"given":"Michelle","family":"Bozovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Edmunds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198911093211906"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.48.5.1104"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1987.03400190090034"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7044.1443"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.4.459"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1001\/jama.1993.03500230097036","article-title":"Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel II)","volume":"269","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"1993","journal-title":"JAMA"},{"key":"e_1_2_1_8_2","first-page":"577","article-title":"Number\u2010needed\u2010to\u2010treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy","volume":"42","author":"Rembold C.M.","year":"1996","journal-title":"J Fam Pract"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440390031005"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.93.10.1796"},{"key":"e_1_2_1_11_2","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"key":"e_1_2_1_12_2","first-page":"91","article-title":"Pharmacist management of a hyperlipidemia clinic","volume":"50","author":"Furmaga E.M.","year":"1993","journal-title":"Am J Hosp Pharm"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1001\/archinte.1995.00430210080012","article-title":"Reducing low\u2010density lipoprotein cholesterol levels in an ambulatory care system","volume":"155","author":"Shaffer J.","year":"1995","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_14_2","volume-title":"Cholesterol treatment: a review of the clinical trials evidence","author":"U.S. General Accounting Office","year":"1996"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1086-5802(16)31059-2"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/j.1875-9114.1996.tb03049.x","article-title":"Economic evaluations of clinical pharmacy services\u20141988\u20131995","volume":"16","author":"Schumock G.T.","year":"1996","journal-title":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1984.tb05858.x"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.14.1533"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00819-9"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.15.1959"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.94.9.2146"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.9.839"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811053391902"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610033351401"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.20.17.1375.34895","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.20.17.1375.34895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:36:29Z","timestamp":1761057389000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.20.17.1375.34895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2000,11]]}},"alternative-id":["10.1592\/phco.20.17.1375.34895"],"URL":"https:\/\/doi.org\/10.1592\/phco.20.17.1375.34895","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,11]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}